Novo Holdings silent on newly created company with million-dollar backing

USD 2.8m (DKK 18m) has been granted to the subsidiary Orbis Medicines, which Novo Holdings founded this week. The holding company doesn't want to comment on anything regarding the new company, however, just as the new director remains silent.

This week, Novo Nordisk fund Novo Holdings founded a new subsidiary named Orbis Medicines, which was at the same time afforded DKK 18m (USD 2.8m), according to registrations in the Danish Central Business Register (CVR). For the time being, however, Novo Nordisk won't comment on the establishment of Orbis Medicines, it tells MedWatch in an email.

It is therefore unclear what exactly the new company will do, but according to its company registration, its purpose is "the research, development and commercialization of medical products, in addition to activities that the board considers to pertain to this."

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs